JNJ reported a 12.6% increase in sales to $20 billion for the first quarter of 2018 as domestic sales grew 6.1% and those from international markets improved about 20%.
Net earnings fell slightly to $4.4 billion or $1.60 per share compared to the prior-year period. After adjusting for certain special items, net earnings amounted to $5.6 billion, or $2.06 per share, beating analyst expectations.
The tax reform has given the company an opportunity to raise its R&D and capital investments in the US by 15% over the next four years. https://news.alphastreet.com/update-1-cancer-drugs-lift-johnson-johnson-earnings/
Net earnings fell slightly to $4.4 billion or $1.60 per share compared to the prior-year period. After adjusting for certain special items, net earnings amounted to $5.6 billion, or $2.06 per share, beating analyst expectations.
The tax reform has given the company an opportunity to raise its R&D and capital investments in the US by 15% over the next four years. https://news.alphastreet.com/update-1-cancer-drugs-lift-johnson-johnson-earnings/